Overview
Conference: March 14-15, 2024
DIA’s Global Labeling Conference is designed for professionals in medical product labeling and related disciplines as they work to develop and manage clear and accurate labeling information for the safe and effective use of prescription drugs, biologics, and medical devices. The efforts of these professionals are key to providing essential information needed by providers, patients, and payers to make decisions about product access, prescription, and use. Influences such as digital technology, patient centricity, evolving product classes, and changing regulations require the use of informed, systematic approaches throughout the labeling cycle to ensure the development and availability of current, compliant information in all regions where products are marketed.
This conference provides a forum for exchange among regulators and industry peers to update their knowledge of key local and global labeling policies and to examine the impact of changes on regulatory compliance. Most importantly, through interactive discussions with expert panels and peer-to-peer exchange, participants will share approaches, processes, and tools to ensure the availability of effective labeling content meeting the needs of patients, consumers, and prescribers.
While we develop our 2024 agenda, please take a moment to review the 2022 final agenda.
Featured
Who should attend?
-
Meeting Designed For
- Labeling
- Regulatory Affairs/Drug Review and Approval Process
- Clinical Safety/Pharmacovigilance
- Pharmacoepidemiology
- Medical Affairs and Communications
- Medical Writing
- Clinical Research and Development
- Product Research and Development Alliances
- Quality Control/Quality Assurance
- Marketing/Advertising/Promotion
Program Committee
-
Kathy Salazar, MA, MBA • Head, Global Labeling Implementation, Global Labeling COE
Janssen Research & Development/Johnson & Johnson, United States -
Rie Matsui, RPh • Senior Director, Regional Labeling Head for APAC
Pfizer Inc, Japan -
Deborah Bebbington • Head Global Labeling
Bayer Plc, United Kingdom -
Lauren Brunke, PharmD, RPh • Senior Director – GRA-NA Global Labeling Department (GoLD)
Eli Lilly and Co, United States -
Theresa Brunone, MA, MS • Head-Labelling Compliance and Implementation, Global Labeling
GlaxoSmithKline, United States -
Megann Looker • Executive Director, Head of Global Labeling
Jazz Pharmaceuticals, United Kingdom -
Gerrit Nijveldt, MSc • Global Labeling Consultant
Opus Regulatory Inc., United States -
Hayley Parker, PhD, MSc • Vice President Regulatory Affairs
PepGen, United States -
Mary Beth Wilusz • Head, Regulatory Labeling Operations and Compliance
Daiichi Sankyo, Inc., United States -
Representative Invited • DIA, United States
-
Steven Bass, PhD • President
Bass Biopharm Consulting Group LLC, United States -
Su-Yueh Lin • Sr. Labeling Consultant, Regulatory Affairs
Taiwan
